Teresa Company Messa: ”Evolution, Commitment, and Innovation” Perfectly Sum up Last Week’s Event
Teresa Company Messa, Market Development Manager at Werfen, shared on LinkedIn:
”Evolution, commitment, and innovation
Three big words, but ones that perfectly sum up last week’s event: the launch of the 70 Series, a new generation of analyzers that mark another step forward in our mission to advance hemostasis diagnostics.
And there could be no better setting than La Pedrera.
Just as Gaudí challenged the limits of his time to transform architecture, we continue to push the limits of technology to transform diagnostics.
And for those of you who are not part of this world, you may ask yourselves: what does this have to do with me?
Everything.
Because behind every sample there is a person, and that person could be you, it could be me.
At Werfen, we work every day with a firm commitment to ensuring the highest quality, accuracy, and service for laboratory professionals and, ultimately, for patients.”
Stay updated with Hemostasis Today.
-
Apr 12, 2026, 14:27Moustafa Abdou: Paroxysmal Nocturnal Hemoglobinuria From a Rare Disease to a Treatable Condition
-
Apr 12, 2026, 14:18Jean Jacques Kiladjian: Grateful to the MSH for the invitation to ‘Highlights of ASH’ in Asia-Pacific 2026
-
Apr 12, 2026, 14:15Paritosh Garg: A fibrotic marrow is not always PMF
-
Apr 12, 2026, 14:13Scott Woller: ACC/AHA Guidelines and the Role of Pulmonary Embolism Response Teams
-
Apr 12, 2026, 13:55Ifeanyichukwu Ifechidere: When Fibrinogen isn’t Really Fibrinogen
-
Apr 12, 2026, 13:53Alan Nurden: A Contemporary Update on the Pathogenesis of Inherited Platelet Dysfunction
-
Apr 12, 2026, 13:47Kalyan Roy: Visual Inspection of Blood Bags and Blood Products
-
Apr 12, 2026, 13:44Francisco Ujueta: PAD VS CAD – Why Individualized Antithrombotic Strategies Matter
-
Apr 12, 2026, 13:42William Aird: Anemia of Inflammation Not Just a Trade-Off but a Possible Compensation